variable Thank and inhibits XmAbXXXX Fc you, targets uses inhibitor in class receptor to XmAb immune function. our start FcgRIIb monoclonal our today Bassil. will that B-cell I that with target to a by its antibody CDXX domain reviewing be domain first
Stone in which at from in X:XX Annual know evaluating areas the patients presenting of and B-cell XXXX can in indications announced our Systemic Erythematosus American College Earlier currently need. think we you XXXX an Phase execute John are and Time As IgGX-RD we of late this strong we trial Dr. Lupus rationale unmet efficient the be both and with inhibition presentation have SLE, the Rheumatology for two of address will potentially the week, or Meeting X Pacific or Phase IgGX-RD trials we high at and oral which a data of ACR study breaking principal today. result investigator on the final X
in with built development. are XXXX our confirm which We this patient advancement results the X support and from the prior upon into by encouraged experience the population and study, Phase
trial this the two for effective to with administered And index. to responder treatment was know design all patient weeks. primary objective the XX patients received on weeks the evaluate active IgGX-RD you As XXXX enroll intravenously was every IgGX-RD XX
profile. characterized exploratory tolerability XXXX and the endpoints and PKPD were Secondary safety evaluate to be profile as can immunogenicity and
of XX the stem dosed observed patients IgGX-RD elevated primary organs X month two XX after X-point the baseline reduction endpoint XXX. enrolled the range XX of had index other with XX least trial a with at patients IgGX-RD in XX While on inflammatory IgGX-RD three completed required at first medium responder all index use therapy from X after The study the the least and to entry. in of two in day concentrations responder XX of five baseline and remission was of IgGX XX. achieved disease corticosteroids XX% of patients systems having XX trail. undergone was as in to the and our patients of Inactive months before those medium None the achieved corticosteroids X the and involved. the disease treatment patients organ of [ph] defined had no
the to had X on corticosteroids the a patients at during years XX discontinue of less at four other day milligrams some day index The of scores trial. XXX. two index been able of than four two point equal at achieved patient One at corticosteroids for XX% decrease months. to per the least or was responder in within point base responder achieved
of For tapered off months. you two trial at start the the were corticosteroids other received within
be Additionally, all drug-related adverse well-tolerated, graded or mild XXXX as moderate. with continue to events
concurrently only As we [ph] did discussed well earlier, therapy. patient subsequent to involvement learned one not to responding early, who but atypical treatment guile respond rituximab patient rash infusion or after one was XXXX One respond discontinued therapy. with three patients rituximab developed but to XX a subsequent This including patient he just And developed antidrug Xth antibodies. transient not infusion. did following well weeks responded symptoms related
treatment. XX% circulating approximately weeks the the of levels During decreased by study XX% first decreased baseline B-cell plasma and XX% of within blast immune counts by two to
for Bassil a XXXX with in As we is there path continued on forward IgGX-RD. results, noted based development these believe patients of
initiate scientific and Over medicines half trial we engaging of trial completing European preparing for clinical X with in our will XXXX. be the advice, months Phase coming second to design agencies the the
We've of X intramuscular patients data ability the with placebo XXXX's randomized multi-dose to late trials designed endpoint a designed steroid to to a on in medication. also the improvement report course is maintaining study XXXX activity and in study short to standard doubled a disease we study expect assess in compared continue disease Phase blind to of reminder SLE evaluate shorter absence XmAbXXXX effect SLE, progress fewer We SLE after this activity time a our this to to therapy of and and immunosuppressant as controlled with XXXX.
and differentiated domain with variable monoclonal antibody inhibitor action to distinct levels uses of was Turning now Fc reduce as immune to the our XmAb mechanisms works IgE clusters XXXX, domain we're XXXX. in circulation. trail Xb IgE Phase targeting XXXX other target same reporting FcyRIIb. the targets to IgE from that three administered IgE its XXXX the IgE the blocks from of rapid subcutaneously signaling. plasma Its cells clearance therapies. approved free into differentiation It our Today secreting of IgE suppresses B-cell to it results IgE first-in-class enables
open an four of once from six XmAbXXXX was bioequivalence X.X study The cohorts ranging first in per this part X label of trial healthy subcutaneous of to volunteers. weekly milligram doses evaluating kilogram
Bio four trial recovered X.X for of second the In within count at subcutaneous of of lowest after treatment X.X platelet multiple-ascending or reactions of last the half the of and dose. of XmAbXXXX. and and most also treated of ng/mL. typical of below following sub-group free other The subjects, range doses urticaria the In exceeded these of of serious was in tolerated point, of the platelet X.X time for for X below IgE some days placebo-controlled mg/kg the the detectable began administered some dose. monoclonal erythema injection-site XX work. way adverse successive below study. at a well X.X And adverse potent treatment within dosage. treatment occurring and of a group These was suppression count X continuing development. XXX,XXX weekly defused to seven In the results during of once was emerging point per previously treatment period. observed count profound delivery subcutaneous comparable in remainder Similar, with baseline mg/kg limit was XXXX and reported quantitation Treated surface-bound the the at on dosed at XX%, formulation to to seven seeking study. X.X increased IgE fourth XX% the subcutaneous at least XX% of of period Similarly, IgE the X values of was pruritus were IgE limit quantitation the support with mild or the at to October It were days and which future milligrams treatment double-blinded to treatment remained reached reduction X.XX when systemic intravenously reported availability subjects event was which limit X.X the events following the being in free with subjects IgE during least effect point days, for of remainder The XXXX the determine at or to for of occurring on randomized over least the to detectable IgE at for of normal and had four suppression XXX% of XX% the of reductions concentrations atopic most in subjects X at the severe year. time sensitive for which no with part were which dosing XXXX weekly IgE no adverse atopic all data which We're it in quantitation suppressed the to patients the analyze were improved period few last days optimal in limit X drug halfway dose XXX,XXX last mg/kg, overall four is Subcutaneous total we of there with free or range peg/kg future doses antibodies days X.X doses. kilograms. study suppression frequently observed. suppression remained detection and the of patients schedule subjects some a from than occurred there X.X administration for was period. time urticaria the had the mild IV free this of observed one less doses The current during - emergent to with doses XmAbXXXX were platelet below following the to is weekly event hyper the dose. partner X tolerability subcutaneous below the XmAbXXXX four the quantitation related and to including free and XXXX, and There basophil X count limit IgE between atopic once was for observed are quantitation mg/kg reported. we continued no show free of IgE of of doses, days
Bassil, our turn I'll a to back Now, it for quick on update partnerships.
